New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
The development of drug-eluting stents is one of the major revolutions in the field of Interventional Cardiology. Restenosis rate has been significantly reduced, in comparison to bare metal stents. The ideal drug to prevent restenosis must have an anti-proliferative and anti-migratory effect on smooth muscle cells but on the other hand must also enhance re-endothelialization, in order to prevent late thrombosis. Additionally, it should effectively inhibit the anti-inflammatory response after balloon induced arterial injury. Currently sirolimus, paclitaxel and more recently, ABT-578-eluting stents are commercially available, but ongoing research and clinical trials will result in new stents coming to market with novel designs loaded with a variety of compounds. As drug-eluting stent implantation becomes more liberal leading to an extensive use of this technology, the problem of restenosis in drug-eluting stents will become more common. However, for the time being, little is known regarding optimal treatment of in-stent restenosis following drug-eluting stent implantation. Future research is mandatory to further clarify, whether these patients should be treated with the same drug-eluting stent, with a different drug-eluting stent or with increased doses.
Vaina
S
S
Department of Interventional Cardiology,Thorax center, Erasmus Medical Center, Rotterdam, The Netherlands.
Ong
A T L
AT
Serruys
P W
PW
D023903:Coronary Restenosis / Q000209:etiology* / Q000517:prevention & control*; D016503:Drug Delivery Systems; D004867:Equipment Design; D006801:Humans; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015607:Stents; D017211:Treatment Failure
D020123:Sirolimus